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in patients with progressive systemic sclerosis* 
Thamine Lessa Andrade1, Aquiles Assunção Camelier2, Fernanda Warken Rosa3, 
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Abstract
Objective: To evaluate the applicability of the 12-Item Short-Form Health Survey (SF-12) as an instrument to measure health-related quality 
of life in a sample of patients with progressive systemic sclerosis (PSS) through the analysis of its reproducibility and its correlation with 
functional and clinical parameters. Methods: A test-retest reproducibility study for the comparative analysis of the intraclass correlation 
coefficients (ICCs) of the SF-12 and the SF-36. A total of 46 patients diagnosed with PSS were studied, regardless of the presence of 
respiratory symptoms. Results: The physical component summary 12 (PCS-12) score had an ICC of 0.47 (95%CI: 0.05-0.71; p < 0.02), 
whereas the mental component summary (MCS-12) score had an ICC of 0.72 (95%CI: 0.49-0.84; p < 0.001). The PCS-36 score had an ICC 
of 0.88 (95%CI: 0.78-0.93; p < 0.001), and the MCS-36 score also had an ICC of 0.88 (95%CI: 0.78-0.93; p < 0.001). Conclusion: The 
SF-12 is a reliable instrument for measuring health-related quality of life in patients with PSS, since it has been proven to be reproducible. 
However, this version of the SF-12 should only be used in clinical research settings.
Keywords: Quality of life; Questionnaires; Statistics; Scleroderma, systemic.
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of patients with PSS, regardless of the presence of 
respiratory symptoms, through the analysis of its 
reproducibility and its correlation with functional 
and clinical respiratory parameters.
Methods
This was a cross-sectional study of a conven-
ience sample comprising forty-six consecutive 
patients monitored between March and December 
of 2004 at the Federal University of Bahia Professor 
Edgard Santos University Hospital Outpatient Clinic 
for Interstitial Diseases, to which they had been 
referred, according to a pre-established evaluation 
protocol, regardless of the presence of respiratory 
symptoms. The diagnosis of PSS (limited and diffuse 
forms) was confirmed in all forty-six patients.
Individuals with environmental or occupational 
exposure, both recognized as potential causes 
of diffuse lung diseases; those with worsening of 
PSS-related symptoms within the past thirty days; 
patients with PSS accompanied by another connec-
tive tissue disease; and those with uncompensated 
chronic comorbidities were excluded from the 
study. Patients who were unable to walk on a flat 
surface, as well as those with presumed difficulties 
in reading and comprehending questionnaires, were 
also excluded. The study design was approved by 
the Ethics in Research Committee of the institution, 
and all participants gave written informed consent.
Patients were evaluated in two consecutive 
visits, with a fifteen-day interval between the two, 
in order to determine clinical stability, which was 
defined as no worsening, no new clinical symptoms, 
and no changes in the current treatment.
The first visit involved administering the SF-12 
and the SF-36 as well as registering demographic 
data and clinical variables using a standardized 
questionnaire, in addition to determining the degree 
of dyspnea using the 1984 Mahler scale.(11) In that 
same visit, spirometry and measurement of pulmo-
nary volumes and DLCO were performed using a 
Vmax 22 device (Sensor Medics Corporation, Yorba 
Linda, CA, USA), in accordance with the guide-
lines established in 2002 by the Brazilian Thoracic 
Society.(12) 
The second visit included evaluating exercise 
capacity using the 6-minute walk test, which was 
performed in accordance with the norms estab-
Introduction
Progressive systemic sclerosis (PSS) is a chronic 
autoimmune disease that is characterized by exces-
sive production of collagen, endothelial cell damage, 
and microvascular obliteration, and usually leads to 
progressive cutaneous-mucosal fibrosis and visceral 
involvement.(1) Pulmonary involvement is common 
and results in high rates of morbidity and mortality. 
Interstitial lung disease (ILD) is the most common 
presentation, being functionally characterized 
by restrictive ventilatory disorder and decreased 
diffusing capacity of the lung for carbon monoxide 
(DLCO).(2) The most common symptom of ILD is 
dyspnea, which contributes, among other factors, 
to reducing the sense of well-being.
There are few clinical conditions that cause, 
over a short period of time, changes in physical 
appearance, in the psychological sphere, and in the 
functional profile that are as significant as those 
typically caused by PSS. All of these changes result 
in a high degree of social inadequacy and signifi-
cant impairment of the quality of life.(3) 
It is known that clinical, radiological, and func-
tional data might not express with precision the real 
impact of the disease on the activities of daily living 
of the individual.(4) The evaluation of health-related 
quality of life through standardized questionnaires 
aims at codifying subjective patient perception with 
objective data, thereby facilitating the analysis of 
this outcome measure in a quantitative research 
environment.(5,6) 
The components of a questionnaire should be 
clear, simply framed, easy to apply and understand, 
and have appropriate administration time.(7) In addi-
tion, such components need to be adapted and 
validated according to the cultural and linguistic 
characteristics of the population to be studied, 
these characteristics being different from those 
from which they originated.(8) In this scenario, the 
12-Item Short-Form Health Survey (SF-12) – a 
more concise version of the SF-36, comprising only 
12 items, whose administration time ranges from 
1 to 2 min – was created.(9) Although the SF-12 has 
already been adapted for use in Brazil, it has only 
been administered to patients with chronic obstruc-
tive pulmonary disease (COPD).(10) 
The objective of the present study was to eval-
uate the applicability of the SF-12 as an instrument 
to measure health-related quality of life in a sample 
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ment was evaluated, the frequency of ILD was 
similar (50% of the cases in each group). Dyspnea 
was reported by thirty-one patients (67.4%). When 
evaluated using the Mahler baseline dyspnea index 
(BDI),(11) the mean score was 7.41. 
The results of the pulmonary function tests are 
shown in Table 1. There was a patient who was 
not able to perform any pulmonary function tests 
due to severe dyspnea. Eight patients (17.4%) 
did not complete the measurement of pulmonary 
volumes due to difficulties in properly carrying out 
the maneuvers. Spirometry results were consid-
ered normal in seven patients (15.6%). Restrictive 
ventilatory disorder was confirmed in twenty-eight 
patients (62.2%), and obstructive respiratory disorder 
was confirmed in ten (22.2%). Of the patients with 
obstructive respiratory disorder, five (50%) were 
smokers or former smokers.
Forty-one patients (89%) completed the 
6-minute walk test. The mean distance covered 
was 454 ± 115.4 m. There were two patients who 
did not perform the test since they were incapable 
of walking freely due to the presence of plantar 
warts. As previously mentioned, the three remaining 
patients did not return for the second visit.
No difficulties in completing the two quality-
of-life questionnaires were reported. No questions 
were left unanswered. The results of the physical 
component summary 12 (PCS-12) and mental 
component summary (MCS-12) scores and of the 
lished by the American Thoracic Society,(13) as well as 
second administrations of the SF-12 and SF-36.
The presence of pulmonary involvement, defined 
as ILD, was evaluated using the high-resolution 
computed tomography (HRCT) database. All patients 
had undergone HRCT, with a maximum interval of 
eighteen months between the date of the examina-
tion and the initiation of the evaluation.
The statistical analysis consisted of descriptive 
data analysis and distribution analysis, according to 
the Kolmogorov-Smirnov test, in order to justify the 
use of parametric tests. The Student’s t-test was used 
to compare the means, and Pearson’s correlation 
coefficient was used to determine the strength of 
the correlations among the variables. Reproducibility 
was evaluated according to the intraclass correla-
tion coefficient (ICC). The continuous variables were 
expressed as mean, standard deviation (SD), and 
95% confidence interval. A value of p < 0.05 was 
considered statistically significant.
Results
Descriptive data
Of the sixty-three patients diagnosed with PSS 
and regularly monitored at the Professor Edgard 
Santos University Hospital Outpatient Clinic for 
Interstitial Diseases, forty-six consecutive patients 
were included in the study, based on the order of 
the appointments, regardless of the presence of 
respiratory symptoms. Three patients (6.5% of the 
initial sample) did not return for the second visit 
and therefore did not complete the study protocol. 
Of those, one patient, who lived outside of the 
city, refused to return, citing transportation diffi-
culties. The other two patients were significantly 
debilitated and were unable to leave home. Of the 
patients studied, forty-one (89.1%) were female, 
and five (10.9%) were male. Ages ranged from 
16 to 71 years, with a mean of 43.2 ± 13.9 years. The 
duration of the disease ranged from 1 to 30 years, 
with a mean of 7.2 ± 6.5 years. The body mass 
index (BMI) ranged from 15 to 38 kg/m2, with a 
mean of 24 ± 5.3 kg/m2. With regard to the pattern 
of cutaneous  involvement, the diffuse form was 
more frequent, occurring in 65.2% of the cases, 
whereas the limited form occurred in 34.8%. When 
the relationship between the pattern of cutaneous 
involvement and the presence of pulmonary involve-
Table 1 - Pulmonary function parameters of the 
46 patients with progressive systemic sclerosis expressed 
in absolute values or in percentages of predicted.
Parameters Mean SD Range
FVC (L) 2.3 0.6 0.9-3.6
FVC (%) 74.9 19.1 31-121
FEV1 (L) 1.8 0.4 0.9-2.6
FEV1 (%) 70.8 16.2 33-117
FEV1/FVC (%) 82.5 9.0 60-109
TLC (L) 3.4 1.1 1.6-6.4 
TLC (%) 72.1 20.1 39-110
Residual volume (%) 77.2 27.8 22-126
DLCO (mL/min/mmHg) 13.4 4.5 4.20-25.4
DLCO (%) 54.4 18.5 18-90
DLCO/AV 71.5 17.5 30-106
SD: standard deviation; FVC: forced vital capacity; FEV1: forced 
expiratory volume in one second; TLC: total lung capacity; 
DLCO: diffusing capacity of the lung for carbon monoxide; and 
DLCO/AV: ratio of DLCO to alveolar ventilation.
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(r = 0.60; p < 0.001); pain (r = 0.43; p < 0.01); 
vitality (r = 0.46; p < 0.01); general aspects of 
health (r = 0.43; p < 0.01); social aspects (r = 0.40; 
p < 0.01); emotional aspects (r = 0.43; p < 0.01); 
and mental health (r = 0.66; p < 0.001). The other 
correlations were not significant (data not shown).
Internal consistency
The internal consistency and the homogeneity 
of the SF-12 were evaluated by determining how 
each question on the SF-12 correlated with the 
PCS-12 and MCS-12 scores using Pearson’s correla-
tion coefficient. The results are shown in Table 3.
Discriminatory power
The patient sample was divided into two 
subgroups, according to several variables clinically 
relevant to PSS, and different cut-off points were 
adopted. The variables studied for the evaluation of 
the discriminatory power were as follows: gender; 
BMI; pattern of cutaneous involvement; pulmo-
nary involvement (ILD or non-ILD); dyspnea; BDI; 
pulmonary function; and distance covered on the 
6-minute walk test. The two subgroups were then 
compared in terms of the mean PCS-12 and MCS-12 
scores for each variable.
physical component summary 36 (PCS-36) and 
mental component summary 36 (MCS-36) scores, 
as well as those of the eight SF-36 domains, are 
shown in Table 2. There was no statistically signifi-
cant difference between the two visits in terms of 
the means of the quality-of-life scores.
Reproducibility
The PCS-12 had an ICC of 0.47 
(95% CI: 0.05-0.71; p < 0.02), whereas the MCS-12 
had an ICC of 0.72 (95% CI: 0.49-0.84; p < 0.001). 
The PCS-36 had an ICC of 0.88 (95% CI: 0.78-
0.93; p < 0.001), and the MCS-36 also had and ICC 
of 0.88 (95% CI: 0.78-0.93; p < 0.001).
Construct validity
The construct validity was evaluated by deter-
mining how the PCS-12 and the MCS-12 correlated 
with each of the eight SF-36 domains, as well as 
with the PCS-36 and MCS-36 scores, using Pearson’s 
correlation coefficient. The PCS-12 correlated 
significantly with the PCS-36 (r = 0.59; p < 0.001); 
the MCS-36 (r = 0.45; p < 0.01); physical capacity 
(r = 0.62; p < 0.01); pain (r = 0.46, p < 0.01); vitality 
(r = 0.59; p < 0.001); and social aspects (r = 0.56; 
p < 0.001). The MCS-12 was significantly correlated 
with the PCS-36 (r = 0.45; p < 0.01); the MCS-36 
Table 2 - Scores of the physical and mental domains of the 12-Item and the 36-Item Short-Form Health Survey and 
scores of the other domains of the 36-Item Short-Form Health Survey in the two visits.
V1 V2 V1-V2 mean difference pa
Domain Mean ± SD
PCS-12 37.3 ± 9.0 38.1 ± 8.9 −0.7 ± 10.6 NS
MCS-12 41.1 ± 10.8 42.8 ± 11.3 −1.8 ± 10.4 NS
PCS-36 38.3 ± 18.9 37.4 ± 16.9 −0.1 ± 4.5 NS
MCS-36 46.4 ± 20.3 44.3 ± 19.7 −0.8 ± 7.0 NS
Physical capacity 37.1 ± 23.8 39.4 ± 24.2 1.5 ± 11.8 NS
Physical aspect 25.5 ± 45.4 16.2 ± 34.0 5.8 ± 20.2 NS
Pain 45.0 ± 22.1 45.9 ± 19.9 −2.3 ± 19.1 NS
General health aspects 43.1 ± 20.4 42.9 ± 20.7 0.09 ± 14.2 NS
Vitality 40.8 ± 20.4 43.0 ± 19.8 −1.7 ± 13.0 NS
Social aspects 57.2 ± 28.6 55.4 ± 27.8 2.6 ± 21.6 NS
Emotional aspects 33.3 ± 40.4 23.2 ± 38.1 9.3 ± 34.3 NS
Mental health 57.5 ± 23.9 56.5 ± 23.7 −0.9 ± 14.9 NS
V1: visit 1; V2: visit 2; SD: standard deviation; NS: not significant; PCS-12: physical component summary 12; MCS-12: mental 
component summary 12; PCS-36: physical component summary 36; and MCS-36: mental component summary 36. ap = V1 vs. V2.
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of the mean MCS-12 scores (data not shown). A box 
plot of the PCS-12 scores in relation to the presence 
of dyspnea is shown in Figure 1.
Suggestion for sample size calculation
We have built a table to be used as a basis for 
planning future studies that will use the SF-12 as 
an outcome measure for the evaluation of quality of 
life in outpatient clinics for ILDs. In this table, the 
various sample sizes were obtained by estimating 
the size of the effect to be detected, considered as 
the variation in the score for each domain after an 
intervention (which ranged from 1 to 10 points for 
each score), taking into account the standard devi-
ation obtained in this study. The suggestions for 
sample size calculation are described in Table 4.
Discussion
Although PSS is a chronic and severely incapaci-
tating disease, little attention has been given to the 
objective evaluation of quality of life of individuals 
with this disease. The SF-12, which has been used 
worldwide, has only recently been validated for use 
in Brazil.(10) There are no studies in the literature 
that have used the SF-12 in individuals with PSS.
The results found in the present study demon-
strate that the SF-12 is reproducible, the ICCs of 
its domains (PCS-12 and MCS-12) having ranged 
from 0.47 to 0.72, with confidence intervals of 
For the pulmonary function parameters, 
forced vital capacity (FVC) and DLCO were used 
(with cut-off points of 50 and 40% of predicted, 
 respectively), since both are clinically relevant 
markers.(12) Since there are no clinically significant 
cut-off points for the 6-minute walk test or for 
BDI in PSS, the median was adopted for identifying 
subgroups with different exercise capacities and 
different degrees of dyspnea. The median distance 
covered (435 m) was used in the evaluation. The 
same criterion was used for the BDI (median, 8). In 
addition, since there is no clinically defined cut-off 
point for BMI in collagenosis, we used the value 
that identified populations with different mortality 
rates for COPD(14): BMI equal to 21 kg/m2. The other 
variables, such as gender, pattern of cutaneous 
involvement, presence of dyspnea, and pulmonary 
involvement, are dichotomous.
The comparison of the mean PCS-12 scores 
only revealed statistical significance when they 
were compared in terms of the presence of dyspnea 
(presence of dyspnea 34.4 ± 8.1; absence of 
dyspnea 43.4 ± 7.9; p < 0.001) and BDI (BDI ≤ 8; 
34.1 ± 6.9 and BDI > 8; 41.2 ± 9.9; p < 0.009). 
The differentiation of the PCS-12 regarding gender, 
BMI, pattern of cutaneous involvement, pulmonary 
involvement, pulmonary function, and distance 
covered was not significant, and neither were any 
Table 3 - Correlation of the twelve questions on the 
12-Item Short-Form Health Survey with the physical 
component summary 12 and the mental component 
summary 12.
SF-12 PCS-12 MCS-12
Question 1 0.45a 0.40a
Question 2 0.47a NS
Question 3 0.61b NS
Question 4 −0.57b NS
Question 5 −0.71b NS
Question 6 NS −0.63b
Question 7 NS −0.51b
Question 8 0.61b NS
Question 9 NS 0.60b
Question 10 0.41a 0.44a
Question 11 NS 0.71b
Question 12 NS NS
SF-12: 12-Item Short-Form Health Survey; PCS-12: phys-
ical component summary 12; MCS-12: mental component 
summary 12; and NS: not significant. ap < 0.01; bp < 0.001.
Yes No
p < 0.001
60
50
40
30
20
Dyspnea
PC
S-
12
 V
1
Figure 1 - Box plot of the physical component summary 
12 score by the presence or absence of dyspnea in visit 1 
(PCS-12 V1).
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However, we observed that, on average, the 
PCS-12 presented lower reproducibility than did the 
PCS-36, which implies the need that a larger sample 
should be allocated to the study of this domain in 
the design phase of future studies (Table 4). The 
ICCs found for the SF-12 indicate, however, that it 
should be used only in clinical trials with an appro-
priate sample design, rather than being administered 
individually in medical appointments.
Despite the low prevalence of PSS, our sample is 
derived from the largest Brazilian cohort study and 
portrays a heterogeneous group of patients with 
different disease spectra, including with various 
degrees of pulmonary involvement.(18) The frequency 
of ILD, evaluated by HRCT, was high (50%). This 
percentage, however, was lower than that reported 
in most publications in which HRCT was also used 
as an evaluation method. These studies reported 
frequencies that ranged from 39 to 91% of the 
cases.(19) Differences in these percentages may result 
from the methodological diversity of the studies, 
including sample bias, since only patients with 
respiratory symptoms were selected, which increases 
the probability of the appearance of this type of 
complication.(20) In addition, we should also consider 
the clinical, demographic, and immunogenetic 
differences among the populations. Most of these 
0.05 to 0.71 and 0.49 to 0.84, respectively. All 
of the results were statistically significant, which 
confirms the SF-12 reproducibility, and, according 
to the analysis of the confidence intervals, similar to 
those reported in the literature, evaluated through 
the superposition of these intervals. However, the 
SF-12 has a slightly lower tendency toward repro-
ducibility. In a study that evaluated 233 individuals 
with rheumatoid arthritis, the 95% confidence 
interval was 0.64 to 0.87 for the ICC of the PCS-12 
and 0.60 to 0.83 for the ICC of the MCS-12.(15) In 
a study of patients with cerebral vascular accident, 
the ICC of the SF-12 was 0.80 (p < 0.05).(16) In the 
2004 Proyecto Latinoamericano de Investigación 
en Obstrucción Pulmonar (Latin American Project 
for the Investigation of Pulmonary Obstruction),(17) 
which was carried out in the city of São Paulo and 
evaluated the SF-12 in a sample of patients with 
COPD, the ICC of the PCS-12 was found to be 
0.69 and the ICC of the MCS-12 was found to be 
0.63. All of these ICC values are within the confi-
dence interval for the patients with PSS evaluated in 
the present study. The SF-36, which, in the present 
study, was adopted as the gold standard for the 
SF-12 and had already been used in other studies 
on PSS, has proven to have good reproducibility, 
with an ICC that ranged from 0.77 to 0.88.
Table 4 - Suggestion for sample size calculation using two 12-Item Short-Form Health Survey subscales in progressive 
systemic sclerosis.
Size of the effect Sample size necessary to detect the differences suggested by the questionnaire 
scores
SF-12
(Range of variation in the 
questionnaire scores)
PCS-12
SD = 10.56
MCS-12
SD = 10.42
E/SD n E/SD n
1 0.09 1571 0.10 1571
2 0.19 394 0.19 394
3 0.28 176 0.28 176
4 0.37 100 0.38 100
5 0.47 64 0.47 64
6 0.57 45 0.57 45
7 0.66 26 0.67 34
8 0.75 21 0.76 26
9 0.85 17 0.86 21
10 0.94 17 0.96 17
SF-12: 12-Item Short-Form Health Survey; PCS-12: physical component summary 12; MCS-12: mental component summary 12; 
E: size of the effect; SD: standard deviation of the means of the differences between visits 1 and 2. Values calculated using a two-
tailed test with an alpha error of 5%, a power of 80%, and parametric distribution.
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that did not have a statistically significant correla-
tion with the PCS-12 had a common denominator 
in that they addressed emotional and subjective 
aspects, which are probably more accurately assessed 
in the mental domain. Another possibility is that 
the correlation of those questions, although weak, 
was not identified due to limitations in the sample 
size, not excluding the possibility of a type II error. 
With regard to the questions that did not present a 
statistically significant correlation with the MCS-12, 
all of them addressed aspects related to physical 
capacity and pain, which are certainly more accu-
rately assessed in the physical domain.
It is known that there are questionnaires that are 
even shorter than the SF-12, such as the SF-8.(29) 
This shorter set of questions is formed by choosing 
those with greater strength of correlation with their 
main domains. The present study provides theo-
retical basis for the future development of shorter 
versions of the SF-12 for use in Brazil.
Several clinical markers, such as dyspnea, exer-
cise capacity, and pulmonary function, correlate 
with a sense of quality of life in diseases involving 
the respiratory tract. Most studies show that, when 
the presence of pulmonary involvement is evalu-
ated, dyspnea correlates better with quality of life 
than do any other symptoms or clinical markers.(30) 
The analysis of the variables considered in the 
present study showed that only dyspnea was a 
significant marker of worsening of quality of life in 
patients with PSS. Therefore, the adoption of meas-
ures aimed at improving the quality of life of such 
patients should, among other things, prioritize the 
reduction of the intensity of dyspnea.
The presence of pulmonary involvement, charac-
terized by ILD on HRCT, did not correlate with worse 
quality of life in our study. The high sensitivity of 
tomography to identify mild forms of ILD, with few 
repercussions in the clinical and functional evalu-
ation, can explain this finding. This observation is 
corroborated by the absence of correlation between 
the pulmonary function parameters (FVC and DLCO) 
and the scores on the physical and mental domains 
of the two questionnaires. The Scleroderma Lung 
Study(27) showed a correlation between decreased 
FVC and worse quality of life. However, the correla-
tion coefficient described was considered too weak 
(r = 0.31). The population evaluated in that study 
also differed from that of the present study in that 
it included patients with a more severe spectrum of 
studies evaluated, almost exclusively, Caucasian 
patients. There is evidence that race-related factors 
can influence the expression of autoantibodies, the 
clinical form of the disease, the pattern of visceral 
involvement, and the prognosis.(21,22) 
From a functional point of view, restrictive 
ventilatory disorder, which is characterized by a 
decrease in total lung capacity or inferred by a 
decrease in FVC, is the pattern most commonly 
described in patients with PSS.(23) In the present 
series, mild restrictive ventilatory disorder occurred 
in most patients. This finding might be explained by 
the methodology of the study, which systematically 
evaluated the patients, regardless of the presence of 
respiratory symptoms, thereby increasing the prob-
ability of identifying functional alterations early, 
when the pulmonary disease is still incipient and 
subclinical.
A decrease in DLCO occurred in most patients, 
including in those cases with no apparent pulmo-
nary involvement (absence of ILD). A decrease in 
DLCO can result form interstitial involvement and 
can also be secondary to pulmonary vascular disease 
caused by PSS, which could explain this functional 
abnormality in patients with normal HRCT scans. 
The evaluation of pulmonary arterial hypertension 
was not within the scope of this study. 
The means found for both questionnaires show 
a decrease in quality of life in all domains evaluated, 
with a greater impact on the physical domain. The 
PCS scores were lower than the MCS scores on both 
questionnaires. One possible explanation for this 
finding is that the disease has a greater impact on 
physical capacity than on mental health, this being 
the most likely explanation, since it reflects what 
has been identified in other studies.(3,24-27) Another 
possible explanation is that the MCS subscale has 
less discriminatory power.
There was a significant correlation between the 
SF-12 and the SF-36, which demonstrates an asso-
ciation between these two instruments. However, the 
strength of the correlation (the ICC) was lower than 
that reported in international studies, but similar to 
that found in a Brazilian sample of patients with 
COPD.(10) This indicates the need to improve these 
scales through further studies.
Internal consistency evaluates how each item 
correlates with the overall score measure of each 
questionnaire.(28) The evaluation of internal consist-
ency of the SF-12 revealed that those questions 
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pulmonary involvement, i.e., patients with at least 
one respiratory symptom, alveolitis, and altered 
pulmonary function parameters.
The present study was carried out in a tertiary 
health care facility and therefore may not represent 
all of the patients with PSS. Future studies should 
seek to include patients from primary and secondary 
health care facilities in an attempt to obtain a more 
representative sample and therefore be able to 
generalize the results.
We can conclude that the SF-12 is a reliable 
instrument for measuring health-related quality of 
life in patients with PSS, since it has been proven 
to be reproducible. Dyspnea was the principal clin-
ical marker of decreased quality of life. The authors 
suggest, however, that this version of the SF-12 
should only be used in clinical research settings.
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